Trial Profile
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Ravagalimab (Primary) ; Ravagalimab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors AbbVie
- 18 Jul 2022 This trial has been discontinued in Italy), according to European Clinical Trials Database record.
- 13 Jan 2022 Status changed from active, no longer recruiting to completed.
- 22 Oct 2021 This trial has been discontinued in Hungary (Global end date: 21 Dec 2021).